Inclusion Criteria:  indication of OGIB:1)after negative upper and lower endoscopy; 2)France: after negative pregnancy test; 3)Hb cut-off male: <13, female: <12  Exclusion Criteria:  Age < 18 years old Known or suspected intestinal obstruction Non-steroidal anti-inflammatory drugs (twice weekly or more) during the 4 weeks preceding enrollment Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule Patient with known gastrointestinal motility disorders Subjects with known or suspected delayed gastric emptying Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions Patient has any allergy or other known contraindication or intolerance to the medications used in the study Patient has any condition, which precludes compliance with study and/or device instructions Patient with any contraindication to take the bowel preparation product Women who are either pregnant or nursing at the time of screening, or are of child- bearing potential and do not practice medically acceptable methods of contraception Concurrent participation in another clinical trial using any investigational drug or device Patient suffers from a life-threatening condition Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters Patients with pace-maker or implantable cardioverter Patient did not sign informed consent Endoscopic placement of the capsule